With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms

After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a next-generation multiple myeloma cell therapy later this year.